Background: Today, continued periodic follow-up of patients treated for colorectal cancer (CRQ seems often to be routine because of tradition, rather than its demonstrated value. Recently, the Norwegian Gastrointestinal Cancer Group (NGICG) has recommended a standard surveillance programme in this malignancy. In this protocol patients are suggested followed for four years with CEA monitoring, ultrasound of the liver, chest radiograph and colonoscopy at regular intervals.
Introduction
Colorectal cancer (CRQ is the most common malignancy in Norway with almost 3,000 cases and more than 1,600 deaths every year. Only half of the patients experience five years survival [1] . World-wide, it is the fourth most common cancer with an estimated 750,000 cases and almost 400,000 deaths every year [2] . Little improvement in this dismal outcome has taken place over the last 30 years [3] . In Norway, the great majority of patients are in Dukes' stage B and C (Duke A -10%, Duke B -30%, Duke C -35%, Duke D -25%) [4] . More than two-thirds undergo radical surgery with curative intention in which all visible tumour is removed. However, almost half of them will eventually develop local or distant recurrence. Phil et al. [5] reported in a study on 1,315 patients, a frequency of recurrence in rectal and colon cancer of 42% and 33%, respectively. More than 30 years have passed since the nonspecific tumor marker carcinoembryonic antigen (CEA) was described in 1965 by Gold and Freedman [6] . Whereas much has been learned about this tumorassociated antigen, the place for CEA monitoring in the follow-up of patients with CRC is still not clarified.
Several authors [7] [8] [9] have argued that a real potential for cure still exists in a small proportion of relapsing CRC patients. However, other investigators have yielded conflicting results regarding an increase in the likelihood of further curative surgery [10] [11] [12] [13] . Schuppisser et al. [7] reported only 5% of patients having any advantage of a follow-up programme. In a meta-analysis of 3,283 patients, Bruinvels et al. [14] sought to determine whether intensive follow-up improved five-year survival. They revealed a 9% increase in survival for patients undergoing close monitoring. The survival advantage for the intensive follow-up group was only significant when clinical follow-up routines containing CEA testing were included. Today, continued periodic follow-up of patients after resection of a CRC seems frequently to be routine because of tradition, rather than its demonstrated value. There is nothing more useless than to do efficiently what should not be done at all. To indicate the cost-effectiveness of the recommended follow-up programme of the Norwegian Gastrointestinal Cancer Group (NGICG) ( Table 1 ) [15] , we performed an economic analysis employing Norwegian cost data, data from the Cancer Registry of Norway and clinical data from the existing English language literature.
Material and methods
Recently, the follow-up programme in CRC has been standardised by the Norwegian Gastrointestinal Cancer Group (NGICG) [15] . This programme (Table 1) was introduced to establish a national high quality follow-up procedure within a reasonable framework of financial and prognostic factors. In this programme, patients are followed for four years with regular CEA monitoring every third month for two years and then twice a year. CEA monitoring is one of the major [4, 16] . Chest radiograph is suggested every six month for two years and then annually. Colonoscopy (in colon cancer) is suggested at one and four years follow-up. In patients having a low anterior resection (LAR) or a total mesorectal excision (TME), rectoscopy is added every three months for two years and then twice a year. This group constitute about half of rectal cancer patients. If relapse is suspected/revealed, the following examinations are suggested: CT scan of abdomen and pelvis, chest radiograph, colonoscopy, bone scan, blood tests (haemoglobin, WBC, trombocytes, creatinin, urea, transaminases, alkaline phosphates, gamma-GT, amylase, bilirubin). Laparotomy is recommended only when a relapse suitable for re-surgery with curative intention is documented.
Ideally, the best estimates for a cost-effectiveness of a follow-up programme should come from prospective randomised trials comparing different follow-up strategies. However, analysis based on different events and data as obtained from a variety of studies has advantages. This information can be structured in a logical and chronologically correct manner. In this cost-effectiveness analysis, the following factors had to be estimated; The frequency of suspected relapse, the number of true relapses, the percentage of deaths/drop outs during follow-up, the basal cost of the NGICG programme and the extra resources spent to document a suspected relapse.
Based on three studies [5, 10, 17] , we assumed 55% of the patients would go through four years follow-up without any sign of recurrence. This group was assumed to go on to live according to the normal life expectancy of equally aged Norwegians. The median age at diagnosis of colon or rectal cancer in Norway in 1993 was 73 years [1] . Life expectancy in Norway at age 73 years is 12 years (females 13.02 years, males 10.19 years, Statistics, Norway 1995). The remaining 45% were assumed suspected for recurrent disease. The median time from surgery to suspicion is reported 10 months [10] . In our model, we calculated all patients followed-up until 10 months and only 62% (no relapse suspected 55% + false relapse 5% + relapse and salvage surgery 2%) from 10 to 48 months due to mortality. This is shown in Figure 1 . Although this is a simplified model overestimating the number of deaths during the second year of follow-up, we will argue that this is compensated for by the underestimation of deaths the first ten months and the fourth year of follow-up. This is visualised in Figure 2 where our model is compared to the national survival data of CRC according to Statistics Norway [1] .
The false positive relapse rate in follow-up programmes containing CEA monitoring, is reported varying from 5%-66%. However, this frequency may be halved by repeated tests before more extensive investigations are initiated [18] . In this study, we calculated the recommended investigation programme disclosed recurrent disease in eight out of nine suspected patients. Patients concluded disease-free, were also considered experiencing a life expectancy of twelve years. Among patients with recurrent disease, about one out of four will be candidates for resurgery [10] . According to Cumunas et aL [10] , one in five of these candidates may possibly be cured after complete surgical removal of recurrences. All these estimates are summarised in Figure  1 . The results of salvage surgery reported by Cumunas [10] is supported by three other studies listed in Table 2 . Minton et al. [18] documented a median gain in survival of about 14 months (36 months vs. 22 months) in operable patients undergoing salvage surgery compared to those who did not undergo reoperation due to a variety of reasons.
The basal cost of the NGICG programme (Table 1 ) and the extra resources spent to document a suspected relapse in 45% of the patients were calculated according to the tariffs of the Norwegian Medical Association (NMA) and the National Insurance Administration (NLA)) [15, [19] [20] [21] . The prices are shown in Tables 3 and 4 .
Statistics
The Microsoft Excel version 7.0 for personal computers was employed for the database and calculations. Costs occurring in the future have to be discounted. In this analysis, we employed a 5% discount rate according to the recommendations of Luce and Elixhauser [22] . All costs were converted to British pounds at the rate of £ 1 = NOK. 10.00.
Results
In this study, the basic cost of just following the NGICG four year follow-up programme, with no sign of recurrence, was estimated to £ 1,232 per patient. CEA moni- toring constituted about 20% of this amount. When adding the cost of extended investigation due to suspected recurrent disease and including surgical intervention in selected subgroups, the figure raised to a total cost of £ 1,943 per patient. The cost included in the follow-up programme was; 10 months follow-up £269, investigation due to suspected relapse in 45% of patients £ 517, cost of resurgery £ 707 and the follow-up from 10-48 months £ 450. The calculation is shown in Table 4 .
A follow-up programme may be of value if it can improve patients' quality of life and /or improve their survival. Based on the figures of Cumunas et al. [10] (2% rescued by resurgery) and Minton and associates [20] (10% gaining 14 months), the cost per life year saved was stipulated ranging between £9,525 and £16,192 ( Table 5) .
The value to put on the years gained can only be speculated. In a prior study in Dukes' B and C CRC at our institution [23] , the quality of life (Qol) was measured 0.83 (1 = best imaginable health status, 0 = dead). The Qol was revealed stable during 2.5 years follow-up and was not significantly influenced by adjuvant chemotherapy. Employing this figure in a cost-utility-analysis, a cost per quality-adjusted-life year (QALY) ranging from £ 11,476 to £ 19,508 can be indicated. Employing a cut off point level of $30,000 (about £ 20,000) per QALY, as proposed by Epstein et al. [24] , the NGICG follow-up programme in CRC looks cost-effective.
Although we would argue that the current study has followed a sound methodology for cost-effectiveness/ cost-utility analysis, we have based our model on different epidemiological and economic assumptions. Whereas the basic cost of the NGICG follow-up programme is reliable, the estimated frequency of suspected recurrent disease (45%), the life years gained and the quality of them is based on prior reports and may not be correct for the Norwegian programme. To clarify limits, we performed a sensitivity analysis varying one of the following three variables at a time: The frequency of salvage surgery, the gain in survival and the quality of life. As shown in Table 6 , a cut off point level of £20,000 per QALY was used. Within this level, the frequency of re-surgery could be raised from 10% to ll%-30%, depending on the survival gain calculated (10.2 years in 2% or 1.2 years in 10%). Looking at survival, the limit to Cost make the NGICG follow-up programme cost-effective is a mean survival gain of 0.12 years in all patients (5.9 years in 2% or 1.2 years in 10%). The corresponding limit in quality of life was 0.46-0.81 depending on the calculated gain in survival.
Discussion
If surgical intervention is potentially curative, any surveillance test that could detect a recurrence when the tumor is still resectable would be useful. However, the possible benefit in this programme must be weighted against the costs and psychologic burdens. These factors include the distress caused by false-positive test results and the fear associated with early detection of an incurable recurrence. The morbidity and mortality related to operations performed on account of either false-or true-positive results can not be ignored. Recently, it has been questioned whether these burdens are compensated for by the possible advantages such as increased life expectancy or improved quality of life (QoL) [19] .
In this article we have tried to evaluate the financial burden and stipulated the possible advantages of the NGICG follow-up programme in CRC patients treated with potentially curative surgery. National cost data and survival figures were combined with results from the English speaking literature. The major findings were a basic cost of the NGICG recommended follow-up programme of £ 1,232 per patient, a total cost including extended investigation and re-surgery of £ 1,943 per patient, an estimated cost per year saved ranging from £9,525 to £16,192 and an assumed cost per QALY between £ 11,476 and £ 19,508 .
In this analysis, we have based our calculation on several assumptions. Among these are the percentage of patients going through the whole follow-up programme and the estimated percentage (2%) rescued by surgical intervention. For simplicity, we have calculated all patients followed for 10 months and then 62% followed from 10 months to four years. In reality there will be a slowly falling curve due to deaths occurring every year as shown in Figure 2 . However, as shown in this figure, there are for practical reasons no differences in economic costs between our model and the survival curve according to Statistics Norway [1] .
We believe that an intensive review programme increases the detection of an early recurrence and thus the likelihood of further curative surgery. However, the advantage of check-up programmes in CRC has been debated [8, 11] . Some investigators have doubted whether there is any advantage at all [11, 25] . They have based their statement on the fact that recurrent disease that can be detected on routine physical examination or symptoms is likely to be advanced and usually not curable. Cumunas et al. [10] concluded 5% of all patients with recurrent disease were long-term survivors, and this represented an increase of only 1.3% in the global survival rates of patients with CRC. They concluded in accordance with Beart and O'Connell [26] that their study did not from a clinical stand point demonstrate any value to an intensive classical postoperative followup programme. However, in spite of this conclusion, they recommended an intensive follow-up protocol. There is no doubt that the great majority of routine examination time have to be spent in seeing outpatients who never develop recurrence. In the study of Cochrane and associates [8] , 72% of the time was spent on nonrelapsing patients and 58% of those who did relapse were diagnosed at times other than those of routine appointments. Symptoms and physical signs are the first sign of relapse in 21%-48% of cases [25, 27] . Beart and O'Connel [26] reported 48 relapses in a group of 168 Dukes' B and C CRC patients. Symptom(s) of relapse were present before or at diagnosis in 85% of the cases (41 of 48). Cochrane et al. [8] concluded prolonged routine outpatient review being doubtful for detecting curable recurrences. When the other aspects of follow-up as providing palliation and detecting operative complications were focused, the benefit was even more doubtful. They concluded that a greater reliance should be placed on the alternative policy of educating patients in symptoms of early recurrence and instructing them to return to their doctor if they developed these symptoms. Based on all these studies, there are at present no indications that make our estimation of curability by resurgery too high. Although we believe our estimate is reasonable, the true frequency may even be below the 2% indicated by Cumunas et al. [10] .
Studies focusing on the cost of surveillance of patients treated with CRC is almost none existent. Improved efficiency and financial accountability are becoming more important in modern health care. It is essential to review time-honoured practices of follow-up continuously to allocate medical resources appropriately. Norfleet [28] reported a cost of $6,299 to follow the recommended surveillance proposed by Moffat and Ketcham [29] for five years. The major cause of a raised financial burden in this study compared to ours were differences in the follow-up programme. They recommended colonoscopy every 12-18th month, quarterly clinical follow-up for the first three years and the costs were not discounted.
In this study, we have presented an economic analysis of a simplified low cost follow-up programme. Such a programme is recommended by several authors [25, 30] . Physical examination, history and CEA monitoring are the pillars in these check-up programmes. The advantage of CEA monitoring has been debated [12] . Preoperative raised CEA levels is strongly associated with stage. In one study, the CEA was elevated in 4%, 25%, 44% and 65% of patients with Dukes' A, B, C and D disease, respectively [7] . Following complete surgical resection of colorectal carcinoma, elevated plasma CEA levels should return to normal within four to six weeks. Kievit et al. [21] concluded that CEA monitoring should not be used for routine following of colon cancer patients as its advantage have so far been demonstrated insufficiently. However, Martin et al. [9] reported in 1980 an impressive 60.5 percent success rate in resecting recurrent lesions first suspected from abnormalities in CEA determinations. On the other hand, Lennon et al. [11] , concluded in a study on 1,414 patients that CEA monitoring could be safely abandoned as an indicator for second-look surgery. Raised CEA levels are reported in 58%-95% of patients having relapse [31, 32] . An expert panel of the American Society of Clinical Oncology (ASCO) reviewed more than 50 articles about postoperative CEA monitoring [33] . The sensitivity for recurrence disease was in one of the best review articles [34] approximately 80% (range 17%-89%). McCall et al. [32] reported a median lead time from first abnormal CEA to diagnosis of recurrent disease by other means of six months (range 1-30 months). Thus, CEA monitoring causes anxiety and fear to several patients due to falsepositive test results. In a series of 60 patients who underwent re-operation based solely on serial elevations in plasma CEA levels, 6.7% of the patients did not have recurrent disease [35] . The frequency of false positive CEA test was reported 6%. In another study [3] , the false positive CEA test was reported 5%. Especially the non-symptomatic patient found to have an elevated plasma CEA level after a presumptive curative resection represents a difficult problem. Martin et al. [3] followed 300 patients after primary resection of CRC from 1971-76 by serial serum CEA determinations. Twenty-two (7.3%) non-symptomatic patients underwent secondlook operations solely because of a rise in CEA. Added to these patients were 124 patients in a prospective study from 1976-84. They concluded 85% (139/146) had recurrences and 58% of these were resectable for potential cure. This policy resulted in a 45% overall incidence of needless laparotomies. Based on this fact, the NGICG recommendation of no laparotomy solely on elevated CEA levels seems reasonable. At present, more and more researchers seem to agree that there is no place for CEA monitoring as an indicator for second-look surgery. This is the basis for CEA monitoring in the NGICG surveillance programme. Excluding the CEA monitoring, the cost may be reduced by f 271 (Table 4) . Employing the other variables in Table 5 unchanged in a cost-utility analysis, the cost per QALY excluding CEA monitoring can be improved from £11,476-£ 19,508 to £9,875-£ 16,787.
In this study, we have not included production gains. It may be argued that this would have reduced the cost of one QALY. However, the usual retire age in Norway is 65 years, and the median age at diagnosis of CRC in Norway was 73 years. Thus, the gain in production will be minimal, especially when calculating a real benefit of 1% of human capital as recommended in a previous study in Hodgkin's disease [36] .
A through evaluation when recurrence is suspected constituted 26% of the follow-up costs in our survey. This recommended programme is a minor version of the study of O'Dweyer et al. [37] . They documented the importance of a through pre-operative evaluation including abdominopelvic CT-scan, bone scan, chest radiograph, colonoscopy, hepatic arteriography, complete blood count, computation of electrolyte levels and renal and liver function tests. They concluded 28% of the non-symptomatic patients were inoperable. 36 operations were performed and resectable intraabdominal disease was revealed in 19 patients (53%). It could be argued that a further minimised version may have improved the cost-effectiveness of the NGICG surveillance programme. The follow-up time may have been shortened and the extended investigations minimised. Relapse in CRC is usually detected within two years follow-up (80%). Berge et al. [17] revealed 92% of all relapses occurring within four years. This indicate a four year programme reasonable. As shown in Table 4 , three days hospitalisation, CTscan of the entire abdomen and pelvis and a bone scan constitute 22% of the extended investigation costs. Thus, an out-patient evaluation would have reduced the costs by £338 per patient. However, the majority of these patients are aged above 70 years. It is therefore several uncertainties concerning an economic success in out-patient evaluation. A minimised use of abdominopelvic CT scan and bone scan may have saved money initially, but this is probably more than balanced by a raised risk of needless laparotomies. We believe the simplified low-cost protocol to be close to the maximum value for money.
Evaluating a problem using this kind of analysis is bound to have certain disadvantages. The problem must be simplified to provide a workable model. Preferably, the result obtained should represent a reasonably accurate quantitative prediction of what results may be expected in reality. The use of variables will then, to a certain extent, have to be limited to those data about which sufficient quantitative information is available in the literature. In this analysis, we have tried to represent the effect of follow-up evaluations in CRC as accurately as is possible on the basis of available literature data. However, the use of models have advantages. Different events and data, as obtained from a variety of studies can be structured in a logical and chronologically correct manner. However, some care must be taken with conclusions based on literature data because large variations are found with respect to the values of many variables required to assess the effect of comprehensive surveillance after curative surgery for CRC.
To generalise cost-effectiveness analysis or cost-utility analysis from one country to another is always difficult in economic analysis. The single cost of each examination listed in Table 3 may differ significantly between countries. However, by employing data from each country in this model, the cost-effectiveness may be estimated. In Western Europe and Northern America we believe these costs being comparable.
In conclusion, we believe this cost-effectiveness approach to the NGICG recommended follow-up programme in CRC has indicated that this simplified low cost surveillance programme look cost effective. If the CEA monitoring as an indicator for second-look surgery is abandoned, the cost-effectiveness may even improve.
